About von Willebrand disease (VWD)
VWD is the most common hereditary bleeding disorder, with approximately 1% of the population having von Willebrand factor (VWF) levels below normal. The symptoms of VWD include frequent nose bleeds, skin bruises and haematomas, prolonged bleeds from small wounds, bleeding in the mouth, and excessive menstrual bleeding. Gastrointestinal bleeding is a common and sometimes life-threatening problem in VWD patients. Severe deficiency of VWF, or a specific defect in the interaction of VWF with FVIII, causes a secondary moderate deficiency of FVIII. These patients may have symptoms that are more characteristic of haemophilia, such as bleeds into joints or muscles.
About Nuwiq®
Nuwiq® (simoctocog alfa) is a 4th generation recombinant factor VIII (rFVIII) protein, produced in a human cell line without chemical modification or fusion with any other protein1. It is cultured without additives of human or animal origin, is devoid of antigenic non-human protein epitopes and has a high affinity for von Willebrand factor1.
Nuwiq® treatment has been assessed in nine1, 2, 3 completed clinical trials which included 201 previously treated patients (190 individuals)1 and 108 previously untreated patients2 with severe haemophilia A. Nuwiq® is available in 250 IU, 500 IU, 1,000 IU, 1,500 IU, 2,000 IU, 2,500 IU, 3,000 IU and 4,000 IU presentations4. Nuwiq® is approved for use in the treatment and prophylaxis of bleeding in patients with haemophilia A (congenital FVIII deficiency) across all age groups4.
About Octapharma
Headquartered in Lachen, Switzerland, Octapharma is one of the largest human protein manufacturers in the world, developing and producing human proteins from human plasma and human cell lines. Octapharma employs nearly 12,000 employees worldwide to support the treatment of patients in 118 countries with products across three therapeutic areas: Immunotherapy, Hematology and Critical Care.
Octapharma has seven R&D sites and five state-of-the-art manufacturing facilities in Austria, France, Germany and Sweden, and operates more than 190 plasma donation centers across Europe and the US. Octapharma has 40 years of experience in patient care.
1) Lissitchkov T et al. Ther Adv Hematol 2019; 10:2040620719858471.
2) Liesner RJ et al. Thromb Haemost 2021; 121:1400–8.
3) Octapharma AG, data on file.
4) Nuwiq® Summary of Product Characteristics